Balchem/$BCPC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Balchem
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Ticker
$BCPC
Sector
Primary listing
Industry
Chemicals
Headquarters
Employees
1,379
ISIN
US0576652004
Website
Balchem Metrics
BasicAdvanced
$5.2B
38.06
$4.17
0.93
$0.87
0.55%
Price and volume
Market cap
$5.2B
Beta
0.93
52-week high
$186.03
52-week low
$145.70
Average daily volume
147K
Dividend rate
$0.87
Financial strength
Current ratio
2.438
Quick ratio
1.292
Long term debt to equity
15.719
Total debt to equity
17.214
Dividend payout ratio (TTM)
20.71%
Interest coverage (TTM)
13.76%
Profitability
EBITDA (TTM)
238.447
Gross margin (TTM)
35.55%
Net profit margin (TTM)
14.16%
Operating margin (TTM)
20.05%
Effective tax rate (TTM)
23.09%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
7.54%
Return on equity (TTM)
11.94%
Valuation
Price to earnings (TTM)
38.057
Price to revenue (TTM)
5.327
Price to book
4.28
Price to tangible book (TTM)
20.73
Price to free cash flow (TTM)
33.984
Free cash flow yield (TTM)
2.94%
Free cash flow per share (TTM)
466.96%
Dividend yield (TTM)
0.55%
Forward dividend yield
0.55%
Growth
Revenue change (TTM)
3.76%
Earnings per share change (TTM)
17.80%
3-year revenue growth (CAGR)
4.62%
10-year revenue growth (CAGR)
4.86%
3-year earnings per share growth (CAGR)
10.28%
10-year earnings per share growth (CAGR)
8.29%
3-year dividend per share growth (CAGR)
10.78%
10-year dividend per share growth (CAGR)
11.23%
What the Analysts think about Balchem
Analyst ratings (Buy, Hold, Sell) for Balchem stock.
Bulls say / Bears say
Balchem reported record net sales of $953.7 million for the full year 2024, a 3.4% increase from the prior year, indicating strong demand across its business segments. (globenewswire.com)
The company launched Optifolin+, targeting the $1.5 billion folic acid market, with expectations of generating $20-30 million in revenue over the next three to four years. (investing.com)
Balchem achieved a 28% increase in net income for Q1 2025, with earnings per share rising to $1.14, surpassing analyst expectations. (simplywall.st)
In Q4 2024, Balchem's earnings per share of $1.03 missed analyst estimates by $0.11, and revenue fell short of expectations, indicating potential challenges in meeting market forecasts. (investing.com)
The Animal Nutrition & Health segment faced challenges in the animal feed additives market, which could impact future revenue growth in this division. (investing.com)
Schroder Investment Management Group reduced its holdings in Balchem, potentially signaling decreased confidence from institutional investors. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Balchem Financial Performance
Revenues and expenses
Balchem Earnings Performance
Company profitability
Balchem News
AllArticlesVideos
Balchem Corporation to Present at the CJS Annual New Ideas Summer Conference on July 10, 2025
GlobeNewsWire·1 day ago
Balchem Corporation to Present at the Wells Fargo Industrials and Materials Conference on June 11, 2025
GlobeNewsWire·4 weeks ago
Balchem Corporation to Participate in the dbAccess Global Consumer Conference on June 4, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Balchem stock?
Balchem (BCPC) has a market cap of $5.2B as of June 27, 2025.
What is the P/E ratio for Balchem stock?
The price to earnings (P/E) ratio for Balchem (BCPC) stock is 38.06 as of June 27, 2025.
Does Balchem stock pay dividends?
Yes, the Balchem (BCPC) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $0.87 and the yield is 0.55%. Balchem has a payout ratio of 20.71% on a trailing twelve-month basis.
When is the next Balchem dividend payment date?
The next Balchem (BCPC) dividend payment date is unconfirmed.
What is the beta indicator for Balchem?
Balchem (BCPC) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.